Does Berberine Shrink Arterial Plaque?

Only one published human study has directly measured berberine’s effect on arterial plaque, and it was small: 21 patients with atherosclerosis who took berberine twice daily for four months showed a modest average decrease in plaque score of about 3%. That is far from the kind of evidence that would let anyone claim the compound reliably shrinks plaque. What does exist is a large body of animal research and cell-culture work showing berberine influences several biological processes tied to plaque formation, from cholesterol handling to inflammation to the health of blood vessel walls. The gap between those laboratory signals and a proven treatment for human plaque buildup remains wide.

The Only Human Plaque Data

The study that gets cited most in discussions of berberine and plaque was published in 2022 in Signal Transduction and Targeted Therapy. Researchers gave 21 atherosclerosis patients oral berberine (500 mg twice daily) for four months and tracked plaque scores. The berberine group saw an average plaque score decrease of 3.2%, while a separate group of 12 patients on standard therapy (a statin plus an antiplatelet drug) actually saw their plaque scores rise by 1.9% over the same period.¹ Those numbers sound impressive, but there are reasons to be cautious. The sample was tiny. The study was not blinded. There was no placebo group. And the comparison arm used different drugs with different mechanisms, so you cannot draw a clean head-to-head conclusion. This was designed more as a pilot observation than a definitive clinical trial.

No large randomized controlled trial has followed up on these findings. Until one does, the honest answer to the title question is: berberine might contribute to plaque reduction, but we do not have the evidence to say it does reliably in humans. What we can do is look at the biological pathways berberine influences and assess whether they line up with the kind of changes that would, in theory, lead to less plaque or more stable plaque over time.

What Animal Studies Show About Lesion Size

The animal literature on berberine and atherosclerosis is much larger and more consistent than the human data. Most of these experiments use a standard model: mice genetically engineered to develop atherosclerosis (ApoE-knockout mice) that are fed a high-fat diet to accelerate plaque buildup. Berberine is then administered to see whether lesions in the aorta shrink or grow more slowly.

In one widely cited study, berberine significantly reduced the severity of atherosclerotic lesions in the aortic arch of these mice. The researchers also found that the effect depended on a specific enzyme pathway (AMPK), because when that enzyme was knocked out, berberine’s anti-atherosclerotic effect weakened considerably.² Another experiment showed that berberine reduced blood lipids, improved the thickening of artery walls, and fought lipid accumulation in the carotid arteries of high-fat-diet mice, likely through a different but related signaling pathway.³

An interesting wrinkle comes from a study of berberine derivatives. When researchers tested plain berberine against two modified versions in ApoE-knockout mice, the modified compounds shrank plaque area significantly, but standard berberine did not produce a statistically significant reduction compared to control mice.⁴ That hints at something important: the form of berberine matters, and the compound as sold in supplements may not always be the most active version. The animal data overall is encouraging, but even among mouse studies the results are not perfectly uniform.

How Berberine Affects Cholesterol

One of the best-supported effects of berberine in humans is its ability to lower LDL cholesterol and triglycerides. Since high LDL is a primary driver of plaque buildup, this is probably the most relevant pathway for anyone wondering about long-term arterial health.

Berberine appears to work partly by increasing the number of LDL receptors on liver cells, which means the liver pulls more LDL out of the bloodstream. At the same time, berberine reduces the liver’s production of a protein called PCSK9, which normally degrades those receptors.⁵ This is the same target that expensive injectable drugs (PCSK9 inhibitors) were designed to hit, though berberine’s effect is much milder. The dual action of boosting LDL receptors while suppressing PCSK9 has been confirmed in multiple studies.⁶

A systematic review and meta-analysis of randomized controlled trials on berberine for dyslipidemia found that it significantly reduced total cholesterol, LDL cholesterol, and triglycerides, and modestly raised HDL cholesterol when used alone. The adverse event rate was no different from control groups.⁷ Another meta-analysis found that adding berberine to simvastatin lowered triglycerides and total cholesterol more than simvastatin alone, with fewer side effects like muscle aches and liver enzyme elevations.⁸ The lipid improvements are real and reasonably well-documented. Whether they are large enough and sustained enough to translate into measurable plaque regression is the unanswered question.

Anti-Inflammatory Effects and Why They Matter for Plaque

Atherosclerosis is fundamentally an inflammatory disease. Plaque does not just form because cholesterol sticks to artery walls; it forms because immune cells infiltrate the artery lining, ingest oxidized LDL, and trigger a chronic inflammatory response. Reducing that inflammation can slow plaque growth and, over time, may allow existing plaque to stabilize or shrink.

A meta-analysis of randomized trials in patients with metabolic syndrome and related conditions found that berberine significantly reduced levels of C-reactive protein (CRP), tumor necrosis factor-alpha (TNF-α), and interleukin-6 (IL-6), all key markers of systemic inflammation.⁹ A separate meta-analysis focused specifically on CRP confirmed the reduction, concluding that berberine may improve chronic inflammation relevant to cardiovascular disease and diabetes.¹⁰

These are human data from pooled randomized trials, which makes them more trustworthy than the plaque-score observations from a single small study. Lowering CRP and inflammatory cytokines is meaningful because elevated inflammation drives plaque progression and increases the risk that existing plaque will rupture, which is what causes most heart attacks and strokes.

Plaque Stability Versus Plaque Size

When people ask whether berberine “shrinks” plaque, the question they really care about is whether it makes their arteries safer. Plaque stability may matter more than plaque size for that purpose. A small, stable plaque covered by a thick fibrous cap is relatively harmless. A large or even medium-sized plaque with a thin cap, lots of inflammatory cells, and active enzyme degradation is the kind that ruptures and triggers a clot.

One cell-culture study showed that berberine reduced the production of an enzyme (MMP-9) and a related protein (EMMPRIN) in activated immune cells. MMP-9 is one of the enzymes that literally chews through the fibrous cap of a plaque, making it vulnerable to rupture. Berberine’s ability to suppress these proteins suggests it could help stabilize plaque and reduce rupture risk, independent of whether plaque volume changes.¹¹

Separately, berberine has been shown in cell models to promote cholesterol efflux from macrophages, the immune cells that gorge on oxidized LDL and become “foam cells,” one of the building blocks of plaque. By enhancing a transport protein called ABCA1, berberine helps these cells pump cholesterol back out, which could theoretically reduce the lipid-rich core of plaque from the inside.¹² Again, these are cell-culture findings, not human outcomes. But they illustrate why researchers keep investigating berberine: it seems to touch multiple steps in the plaque-formation process rather than just one.

The Gut Microbiome Connection

One of the more novel findings about berberine involves a metabolite called TMAO (trimethylamine N-oxide). Certain gut bacteria convert dietary choline and carnitine into trimethylamine (TMA), which the liver then oxidizes to TMAO. Elevated TMAO levels are associated with accelerated atherosclerosis. Berberine appears to reshape the gut microbiome in a way that reduces TMA production, which in turn lowers TMAO levels.

In mice fed a choline-enriched diet designed to boost TMAO, berberine reduced both TMA and TMAO levels and decreased atherosclerotic lesion size. Analysis of the animals’ gut bacteria showed that berberine altered the microbial composition and reduced the abundance of genes responsible for TMA production.¹³ The same research group behind the human plaque study mentioned earlier proposed that this gut-microbiome mechanism is a key part of berberine’s anti-atherosclerotic effect.¹ The TMAO pathway is attracting growing attention in cardiovascular research, and berberine’s effect here gives it a mechanism of action distinct from conventional lipid-lowering drugs.

Endothelial Health and Arterial Stiffness

Healthy arteries rely on a functioning endothelium, the thin inner lining that regulates blood flow, prevents clotting, and keeps the vessel wall from stiffening. Damage to the endothelium is one of the earliest events in atherosclerosis. Several laboratory studies suggest berberine protects endothelial cells from stress.

In cultured endothelial cells and isolated rat blood vessels, berberine boosted production of nitric oxide (the molecule that relaxes arteries), reduced oxidative stress, suppressed inflammatory signaling, and prevented immune cells from sticking to the vessel wall. These protective effects were traced back to activation of AMPK, the same enzyme pathway implicated in berberine’s anti-plaque effects in mice.¹⁴ Similar findings came from studies on endothelial cells exposed to high levels of fatty acids and from carotid arteries of hypertensive rats.¹⁵¹⁶

Beyond the endothelium itself, berberine may also reduce arterial stiffness. In hypertensive rats, berberine preserved arterial elasticity and maintained endothelium-dependent relaxation.¹⁷ In ApoE-knockout mice given berberine for a full year, mean blood pressure and pulse pressure both dropped significantly, and the effect appeared to work through suppression of a specific ion channel involved in vascular stiffening.¹⁸ Arterial stiffness is itself a predictor of cardiovascular events, so even if berberine does not directly shrink plaque, keeping arteries more elastic could reduce risk through a parallel pathway.

The Bioavailability Problem

Here is where the promise runs into a practical wall. Berberine’s oral bioavailability is estimated at less than 1%, meaning that the vast majority of a swallowed dose never reaches the bloodstream in active form.¹⁹ The reasons include poor solubility, low permeability across the gut lining, active pumping back out of cells by a transporter protein called P-glycoprotein, and extensive metabolism in both the liver and the intestines.²⁰

This creates a paradox: berberine clearly does things in human trials (lowers cholesterol, reduces blood sugar, cuts CRP), yet almost none of it gets absorbed. One explanation is that much of berberine’s activity happens in the gut itself. The TMAO-reducing effect, for example, depends on berberine interacting with bacteria in the intestines, not on berberine circulating through the blood to reach arterial walls. Gut-level effects on bile acid metabolism and lipid absorption may also contribute. Still, for any mechanism that requires berberine to reach arterial tissue directly, the low absorption is a genuine obstacle.

Researchers are working on enhanced-absorption formulations using nanoparticles, lipid carriers, and co-administration with compounds that inhibit P-glycoprotein (piperine from black pepper is a common pairing). Some of these formulations have shown improved blood levels in early testing, but none has been validated in a large cardiovascular trial.

Drug Interactions Worth Knowing About

Berberine is widely sold as a supplement, and many people take it alongside prescription medications without mentioning it to their doctors. This is riskier than it sounds, because berberine inhibits several of the liver enzymes responsible for breaking down common drugs.

In a human study, repeated berberine dosing strongly suppressed the enzyme CYP2D6 and moderately inhibited CYP2C9 and CYP3A4. For CYP3A4, the blood levels of a test drug (midazolam) rose by about 40% after berberine treatment, meaning the drug was cleared more slowly and accumulated in the body.²¹ CYP3A4 and CYP2D6 together metabolize a huge fraction of prescription drugs, including many statins, blood thinners, antidepressants, and heart medications. A review of berberine’s effects on these enzymes concluded that healthcare providers should investigate potential interactions before recommending the supplement, and that clinical trials are needed to quantify the risk in real patients.²²

If you are taking a statin, a blood thinner, or any drug metabolized by CYP3A4 or CYP2D6, adding berberine could effectively increase the dose of that drug in your body without your cardiologist knowing it. The irony is that the people most interested in berberine for arterial plaque are exactly the people most likely to be on these medications already.

Berberine’s Metabolic Effects and the Bigger Cardiovascular Picture

Much of the human trial data on berberine comes from studies on type 2 diabetes and metabolic syndrome rather than atherosclerosis directly. In a trial of 48 adults with poorly controlled type 2 diabetes, three months of berberine lowered hemoglobin A1c (a measure of average blood sugar) from about 8.1% to 7.3%, cut fasting insulin by roughly 28%, and reduced insulin resistance by about 45%. Total cholesterol and LDL cholesterol dropped significantly as well.²³ A later meta-analysis of randomized trials confirmed that berberine, used alone or alongside standard diabetes medications, reliably reduced blood sugar measures and improved insulin resistance and BMI.²⁴

This matters for plaque because insulin resistance, high blood sugar, and metabolic syndrome are all independent accelerators of atherosclerosis. By improving these metabolic parameters, berberine could slow plaque progression indirectly, even if it never touches an artery wall. For people whose atherosclerosis is being driven partly by metabolic dysfunction, that indirect benefit might be just as meaningful as a direct anti-plaque effect. But it would take years of follow-up in thousands of patients to prove that these metabolic improvements translate into fewer heart attacks or measurably smaller plaques. Those trials have not been done.

How Berberine Compares to Proven Therapies

Statins, the standard treatment for atherosclerosis, have been studied in hundreds of thousands of patients over decades. High-intensity statins can shrink plaque volume by a few percent over one to two years, as demonstrated repeatedly by intravascular ultrasound studies. Berberine has nothing close to that evidence base. The single 21-patient study showed a directionally promising result, but comparing that to the mountain of statin data would be misleading.

Where berberine may have a role is as an add-on or alternative for people who cannot tolerate statins. The meta-analysis finding that berberine plus simvastatin lowered triglycerides and total cholesterol more than simvastatin alone, with fewer side effects, is worth paying attention to.⁸ For patients who experience muscle pain on statins (one of the most common reasons people stop taking them), berberine’s lower rate of that particular side effect is appealing. But “better tolerated” and “proven to reduce cardiovascular events” are very different claims, and only the first one has support right now.

Nobody in mainstream cardiology is recommending berberine as a replacement for proven cardiovascular therapies. The most responsible framing is that berberine is a biologically active compound with multiple mechanisms relevant to atherosclerosis, supported by strong preclinical data and modest human evidence on surrogate markers like LDL, CRP, and blood sugar. Whether those mechanisms add up to meaningful plaque regression or reduced heart attack risk in real patients remains genuinely unknown.